Syncom Formulations Stock Price Analysis and Quick Research Report. Is Syncom Formulations an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Syncom Formulations. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Syncom Formulations has a PE ratio of 29.549579277347 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Syncom Formulations has ROA of 6.1483% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Syncom Formulations has a Current ratio of 2.7631.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Syncom Formulations has a ROE of 8.7096%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Syncom Formulations has a Debt to Equity ratio of 0.2501 which means that the company has low proportion of debt in its capital.

• Sales growth: Syncom Formulations has reported revenue growth of 15.0085% which is fair in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Syncom Formulations for the current financial year is 10.8766231252874%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Syncom Formulations is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Syncom Formulations is Rs 0.6061. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Syncom Formulations in Ticker for free. Also, one can get the intrinsic value of Syncom Formulations by using Valuation Calculators, which are available with a Finology ONE subscription. 

Syncom Formulations FAQs

Q1. What is Syncom Formulations share price today?
Ans: The current share price of Syncom Formulations is Rs 17.91.

Q2. What is the market capitalisation of Syncom Formulations?
Ans: Syncom Formulations has a market capitalisation of Rs 1683.54 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Syncom Formulations?
Ans: The PE ratio of Syncom Formulations is 29.549579277347 and the P/B ratio of Syncom Formulations is 4.73396241376576, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Syncom Formulations share?
Ans: The 52-week high share price of Syncom Formulations is Rs 23.87, and the 52-week low share price of Syncom Formulations is Rs 14.1.

Q5. Does Syncom Formulations pay dividends?
Ans: Currently, Syncom Formulations does not pay dividends. Dividend yield of Syncom Formulations is around 0%.

Q6. What are the face value and book value of Syncom Formulations shares?
Ans: The face value of Syncom Formulations shares is Rs 1, while the book value per share of Syncom Formulations is around Rs 3.7833. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Syncom Formulations?
Ans: Syncom Formulations has a total debt of Rs 71.6503 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Syncom Formulations?
Ans: The ROE of Syncom Formulations is 8.7096% and ROCE of Syncom Formulations is 10.4561%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Syncom Formulations a good buy for the long term?
Ans: The Syncom Formulations long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Syncom Formulations undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Syncom Formulations appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Syncom Formulations’s financials?
Ans: You can review Syncom Formulations’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.